Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jon Greenberg

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
GMHC Treatment Issues : the Gay Men'S Health Crisis Newsletter of Experimental AIDS Therapies|August 14, 2003
"Alternative" treatment activismJon Greenberg
The International Journal of Artificial Organs|February 28, 2024
Physiologic benefits of veno-pulmonary extracorporeal membrane oxygenation for COVID-19 ARDS: A single center experienceJohn C Grotberg, Jon Greenberg, Mary Sullivan, et al.
Lung Cancer (Amsterdam, Netherlands)|October 24, 2013
A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancerMartin Reck, Maciej Krzakowski, Ewa Chmielowska, et al.
Clinical Pharmacology in Drug Development|March 21, 2023
Dosing Recommendation Based on the Effects of Different Meal Types on Pexidartinib Pharmacokinetics in Healthy Subjects: Implementation of Model-informed Drug Development StrategyHamim Zahir, Ophelia Yin, Ching Hsu, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 2, 2023
Application of the model-informed drug development paradigm to datopotamab deruxtecan dose selection for late-stage developmentYasong Lu, Shuang Liang, Ying Hong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2023
First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01Toshio Shimizu, Jacob Sands, Kiyotaka Yoh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 30, 2026
Erratum: First-In-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01Toshio Shimizu, Jacob Sands, Kiyotaka Yoh, et al.
Elife|December 23, 2022
Predicting progression-free survival after systemic therapy in advanced head and neck cancer: Bayesian regression and model developmentPaul R Barber, Rami Mustapha, Fabian Flores-Borja, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
GMHC Treatment Issues : the Gay Men'S Health Crisis Newsletter of Experimental AIDS Therapies|August 14, 2003
"Alternative" treatment activismJon Greenberg
The International Journal of Artificial Organs|February 28, 2024
Physiologic benefits of veno-pulmonary extracorporeal membrane oxygenation for COVID-19 ARDS: A single center experienceJohn C Grotberg, Jon Greenberg, Mary Sullivan, et al.
Lung Cancer (Amsterdam, Netherlands)|October 24, 2013
A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancerMartin Reck, Maciej Krzakowski, Ewa Chmielowska, et al.
Clinical Pharmacology in Drug Development|March 21, 2023
Dosing Recommendation Based on the Effects of Different Meal Types on Pexidartinib Pharmacokinetics in Healthy Subjects: Implementation of Model-informed Drug Development StrategyHamim Zahir, Ophelia Yin, Ching Hsu, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 2, 2023
Application of the model-informed drug development paradigm to datopotamab deruxtecan dose selection for late-stage developmentYasong Lu, Shuang Liang, Ying Hong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2023
First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01Toshio Shimizu, Jacob Sands, Kiyotaka Yoh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 30, 2026
Erratum: First-In-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01Toshio Shimizu, Jacob Sands, Kiyotaka Yoh, et al.
Elife|December 23, 2022
Predicting progression-free survival after systemic therapy in advanced head and neck cancer: Bayesian regression and model developmentPaul R Barber, Rami Mustapha, Fabian Flores-Borja, et al.
Pageof 1